Sanford Markowitz
Corporate Officer/Principal en Case Western Reserve University School of Medicine .
Perfil
Sanford Markowitz was the founder of Rodeo Therapeutics Corp.
which was founded in 2017, where he held the title of Director.
Currently, he is a Professor at Case Western Reserve University School of Medicine since 1988.
Previously, he was a Director at Lucid Diagnostics, Inc. Dr. Markowitz received his undergraduate degree from Harvard University and his doctorate from Yale University.
Cargos activos de Sanford Markowitz
| Empresas | Cargo | Inicio |
|---|---|---|
| Case Western Reserve University School of Medicine | Corporate Officer/Principal | 01/01/1988 |
Antiguos cargos conocidos de Sanford Markowitz.
| Empresas | Cargo | Fin |
|---|---|---|
| LUCID DIAGNOSTICS INC. | Director/Miembro de la Junta | - |
Rodeo Therapeutics Corp.
 Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Fundador | - |
Formación de Sanford Markowitz.
| Harvard University | Undergraduate Degree |
| Yale University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| LUCID DIAGNOSTICS INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Rodeo Therapeutics Corp.
Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Sanford Markowitz
